Ikena Oncology grabs $120m Series B

Ikena Oncology Inc, a developer of patient-directed, biomarker-driven cancer therapies, has secured $120 million in Series B financing.

5 January 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles